Fondaparinux for VTE Prophylaxis After Hip Arthroplasty
Administer fondaparinux 2.5 mg subcutaneously once daily, starting 6-8 hours postoperatively, and continue for 10-14 days minimum with consideration for extended prophylaxis up to 35 days in high-risk patients. 1
Dosing and Timing
Standard Dosing:
- 2.5 mg subcutaneously once daily for all patients undergoing hip arthroplasty 1, 2
- First dose: 6-8 hours after surgical closure 1, 2
- Alternative flexible timing: The morning after surgery is equally effective and safe, with no significant difference in symptomatic VTE (2.0% vs 1.9%) or bleeding rates 3
Duration:
- Minimum 10-14 days for standard prophylaxis 1
- Extended prophylaxis up to 35 days should be strongly considered for high-risk patients 1
- Extended prophylaxis after hip fracture surgery dramatically reduces delayed VTE from 35.0% to 1.4% (p<0.001) 4
Renal Function Criteria and Dose Adjustments
Critical renal function thresholds:
- CrCl ≥50 mL/min: Standard dose 2.5 mg once daily 2
- CrCl 30-50 mL/min: Reduce to 1.5 mg once daily 1, 5
- CrCl <30 mL/min: CONTRAINDICATED 1, 2
The 1.5 mg reduced dose in moderate renal impairment (CrCl 30-50 mL/min) has been validated in real-world practice with acceptable safety: major bleeding rate of 4.5% at day 10 and symptomatic VTE rate of 0.5% 5. Fondaparinux clearance is approximately 40% lower in moderate renal impairment and 55% lower in severe renal impairment compared to normal function 2.
Important caveat: Use creatinine clearance (CCr) calculated by Cockcroft-Gault, NOT eGFR, for dosing decisions. Using eGFR instead of CCr significantly increases bleeding risk (25.7% vs 6.0%, p<0.05) in patients with small body surface area 6.
Absolute Contraindications
- Creatinine clearance <30 mL/min 1, 2
- Body weight <50 kg (30% decreased clearance increases bleeding risk) 2
- Active major bleeding 2
- Bacterial endocarditis 2
- Severe hypersensitivity to fondaparinux 2
Relative Contraindications and High-Risk Situations
Use with extreme caution or avoid in:
- Age >75 years: 25% lower clearance; monitor closely 2
- Moderate hepatic impairment: Higher bleeding incidence observed despite similar pharmacokinetics 2
- Thrombocytopenia: Monitor platelet counts every 2-3 days up to day 14, then every 2 weeks 7
- Neuraxial anesthesia planned: Coordinate timing carefully to avoid spinal/epidural hematoma 8
Efficacy and Safety Profile
Fondaparinux demonstrates superior VTE prevention compared to LMWH:
- 50.6% relative risk reduction in VTE (6.8% vs 13.7%, p<0.001) 4
- DVT reduction: RR 0.75 (95% CI: 0.56-1.00) 9
- VTE reduction: RR 0.59 (95% CI: 0.48-0.71) 9
Bleeding considerations:
- Major bleeding rate: 2.7% in hip replacement surgery 2
- Significantly higher major bleeding than LMWH (RR 2.06,95% CI: 1.19-3.57) 9
- Most major bleeding events (≥75%) occur within first 4 days post-surgery 2
- Surgical site bleeding increased (RR 1.67) 9
Critical Monitoring Requirements
- Baseline: CBC with platelet count, serum creatinine, stool occult blood 7
- During therapy: Hemoglobin, hematocrit, platelet count every 2-3 days up to day 14, then every 2 weeks 7
- Anti-Xa monitoring: Not routinely required but can be measured using fondaparinux-specific calibrator (NOT heparin standards) if unexpected bleeding or coagulation changes occur 2
- Expected anti-Xa levels: Peak 0.39-0.50 mg/L at ~3 hours; trough 0.14-0.19 mg/L 2
Reversal and Bleeding Management
No specific antidote exists for fondaparinux. 10
If severe bleeding occurs:
- Prothrombin complex concentrates (PCCs): 25-50 IU/kg 10
- Recombinant Factor VIIa: 90 mcg/kg (effect limited to 6 hours) 10
- Protamine is INEFFECTIVE 10
Special Populations
Elderly patients (>75 years): Use standard dose but monitor closely; 25% lower clearance increases exposure 2
Cancer patients: Fondaparinux is an acceptable option at 2.5 mg once daily for surgical prophylaxis 8, 11
Patients unable to use heparins: Fondaparinux provides an alternative when heparin-induced thrombocytopenia is a concern, as it does not bind to platelet factor 4 2